People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...
Once-weekly prophylaxis with efanesoctocog alfa (Altuviiio) led to high sustained factor VIII activity and was effective in preventing bleeding among children with severe hemophilia A, the phase III ...
Altuviiio temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. The Food and Drug Administration (FDA) has approved Altuviiio ™ (antihemophilic factor [recombinant] ...
Please provide your email address to receive an email when new articles are posted on . In this video, Lindsey A. George, MD, talked about improving the function of factor VIII variants for hemophilia ...
But Why Tho? on MSN
REVIEW: ‘X-Factor’ Issue 8
X-Factor Issue 8 is published by Marvel Comics. Written by Mark Russell, art by Bob Quinn, colors by Jesus Aburtov and letter ...
Valoctocogene roxaparvovec delivers a B-domain–deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results